ProGnosis Biotech Lateral Flow Technology
Lateral flow assay or LFAs are simple to use diagnostic devices utilized to rapidly confirm the presence or absence of a target molecule, such as proteins in human specimens, toxins in animal feeds or antibiotics in dairy products.
ProGnosis Biotech’s LFAs have a control line to ensure the tests are working according to specification, along with one or more target test lines. Our Lateral Flow Assays are designed to incorporate intuitive user workflows requiring minimal hands-on training time. They can be qualitative and read visually, or quantitative when operated with our reader technology, Lateral Logic.
Streamlined Lateral Flow Assay Kits, open-and-analyze your samples!
Our Lateral Flow Immunoassay technology is designed according to our customer assay requirements. We typically combine a nitrocellulose membrane, colored nanoparticles, and specific antibodies to deliver consistent and accurate results. The most commonly Lateral Flow Immunoassays designed for the industries we serve use: capture or “sandwich” format and “competitive” format.
The sandwich LFA format is typically used for detecting larger molecules that have epitopes (e.g., 2 binding sites). The way they operate is quite straightforward: An antibody is attached to a binding site conjugated to a nanoparticle, and another antibody attached to another binding site is used to derive the test line. When the target molecule is present, the analyte will bind to both the antibody attached to the nanoparticle and to the antibody on the test line, deriving a visual signal.
This signal intensity can be qualitatively interpreted or quantitatively analyzed using the ProGnosis Biotech S-Flow Reader operated with the Lateral Logic software. The sandwich format results in single intensity at the test line that is directly proportional to the amount of analyte present in the sample.
On the other hand, the competitive Lateral Flow Assay format is used for detecting analytes when their antibody pairs are not present or if the analyte is too small for multiple antibody binding sites, such as antibiotics and tetracyclines in dairy products. Using this format, the test line typically contains the analyte of interest, and a conjugate pad contains the detection antibody-nanoparticle pair. Typically this format is used to check if the analyte of interest is NOT present, thus leading the conjugates into binding to the analyte at the test line, yielding a signal.
This signal intensity can also be qualitatively interpreted or quantitatively analyzed using the ProGnosis Biotech S-Flow Reader operated with the Lateral Logic software. In the competitive format, the signal intensity is inversely proportional to the amount of analyte present in the sample.
Our continuous technical developments in our unique Lateral Logic Lateral Flow Assay analytical technology and advancements in the raw materials we formulate, often match the sensitivity and quality of our ELISA kits.